NxStage Board Member Dr. Barry M. Straube Honored with Prestigious Award from the American Association of Kidney Patients

LAWRENCE, Mass., Sept. 26, 2011 /PRNewswire via COMTEX/ —

NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that Barry M. Straube, M.D., a member of its Board of Directors, was honored with the Peter Lundin, MD Award from the American Association of Kidney Patients (AAKP) at the organization’s 38th Annual Convention in August. The AAKP presents the award yearly to an outstanding renal physician who makes contributions to the care, welfare and well-being of patients over a lifetime of devoted service.

(Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO )

The award is named for a former President of AAKP, Peter Lundin, who was both a nephrologist and an end-stage renal disease (ESRD) patient. Dr. Straube is the immediate past Chief Medical Officer for the Centers for Medicare & Medicaid Services (CMS), as well as the immediate past director of the CMS Office of Clinical Standards & Quality (OCSQ). Among his many diverse duties at CMS, he chaired the End Stage Renal Disease (ESRD) and Clinical Laboratory Open Door Forum and acted as a senior advisor on ESRD and transplantation issues to the agency. He is a board-certified nephrologist and led CMS efforts in kidney quality metrics development and use, kidney disease quality improvement initiatives, development of the ESRD bundled payment and Quality Incentive Programs, creation of the CROWNWeb ESRD data collection initiative, and many other initiatives focused on improving the quality and value of care delivered to patients with kidney disease.

It is a great privilege to receive the Peter Lundin Award, said Dr. Straube. I truly believe that all patients should be informed of their therapy options and have access to the therapy that is right for them. I am confident that we can continue to advance patient care with greater access to more frequent hemodialysis, which can lead to improved quality of life, better health outcomes and associated lower costs when delivered in the patient’s home. I am honored to be recognized by such a strong and growing community of patients with whom I share this goal.

Dr. Straube’s long- term commitment to improving the lives of kidney patients has had a major influence on shaping policy and standards of care within the renal care community, said Jeffrey Burbank, Chief Executive Officer, NxStage. We are very pleased that the AAKP has recognized Dr. Straube’s significant contributions with this prestigious and most deserving award.

About the NxStage System One

The NxStage System One is the first and only truly portable hemodialysis system cleared for home use by the U.S. Food & Drug Administration (FDA). Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients’ homes and give patients the freedom to travel with their therapy. When combined with the NxStage Pureflow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, at home or on vacation.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq:NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. NxStage is leading the development of the home hemodialysis market in the US with the only portable hemodialysis machine, the System One, cleared for home use by the FDA. For more information on NxStage and its products, please visit the company’s website at https://www.nxstage.com/.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words anticipate, believe, expect, estimate, plan, and similar expressions are generally intended to identify forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage’s control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements including market acceptance and demand for NxStage’s System One, growth in home hemodialysis, and certain other factors that may affect future operating results and which are detailed in NxStage’s filings with the Securities and Exchange Commission, including Quarterly Report on Form 10Q for the quarter ended June 30, 2011. In addition, the statements in this press release represent NxStage’s expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage’s expectations or beliefs as of any date subsequent to the date of this press release.

Media Contacts:
Kristen Sheppard, Esq.
Vice President, Investor Relations
NxStage Medical, Inc.
ir@nxstage.com
978-332-5923

SOURCE NxStage Medical, Inc.